Zobrazeno 1 - 3
of 3
pro vyhledávání: ''
Autor:
Daisuke Gomi, Narikazu Boku, Yusuke Tanigawara, Tsunehiro Takahashi, Hirofumi Kawakubo, Hiroya Takeuchi, Kenzo Soejima, Yuko Kitagawa, Kazunari Tateishi, Takashi Ichiyama, Takuro Mizukami, Yasuo Hamamoto, Chiyo K. Imamura, Eisuke Booka
Publikováno v:
Gastric Cancer
Background S-1 is an oral anticancer drug, containing tegafur (a prodrug of 5-fluorouracil, 5-FU), 5-chloro-2,4-dihydroxypyridine, and potassium oxonate. As renal dysfunction is known to increase exposure of 5-FU following S-1 administration, the inc
Autor:
Jian Li, Jinwan Wang, Yi Ba, Weichang Chen, Yunpeng Liu, Leizhen Zheng, Tianshu Liu, Rui-Hua Xu, Dong Ma, Shunchang Jiao, Yongqian Shu, Lin Shen, Yuxian Bai, Shukui Qin, Guanghai Dai, Nanfeng Fan, Jianming Xu
Publikováno v:
Gastric Cancer
Background The V325 study showed that docetaxel, cisplatin, and fluorouracil (DCF) prolonged overall survival (OS) of patients with advanced gastric cancer, but with a high incidence of dose-limiting toxicities. We investigated the efficacy and safet
Autor:
Guanghai Dai, Lin Shen, Shukui Qin, Shiying Yu, Liwei Wang, Lilian Bu, Zhenzhou Yang, Rui-Hua Xu, Jinwan Wang, Yongzhe Piao, Yongqian Shu, Lei Chen, Yunpeng Liu, Hongming Pan, Jianming Xu, Jin Li
Publikováno v:
Gastric Cancer
Background In the AVAGAST study, fluoropyrimidine and cisplatin plus bevacizumab did not significantly improve overall survival (OS) versus fluoropyrimidine and cisplatin plus placebo in patients with advanced gastric cancer. Geographic differences i